Hetao Huang, Minghui Luo, Haodong Liang, Jianke Pan, Weiyi Yang, Lingfeng Zeng, Guihong Liang, Senrong Hou, Jinlong Zhao, Jun Liu
Journal: Pain medicine (Malden, Mass.) 2021;22(2):352-362
PMID: 32797224
OBJECTIVE
To compare the efficacy and safety of celecoxib and diclofenac sodium in patients with knee osteoarthritis (KOA).
METHODS
Clinical controlled trials (CCTs) and randomized controlled trials (RCTs) from online databases comparing the efficacy of celecoxib and diclofenac sodium in the treatment of KOA were retrieved. The main outcomes included the treatment effect, C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), visual analog scale (VAS) score, and complication rate. The Cochrane risk of bias (ROB) tool in Review Manager 5.3.5 was used to assess methodological quality.
RESULTS
Twelve studies (N = 2,350) were included in this meta-analysis. The meta-analysis indicated that celecoxib reduced pain more effectively than diclofenac sodium in patients with KOA, as evaluated by the VAS score. In addition, celecoxib has certain advantages in terms of better treatment effects and greater reductions in the ESR, CRP level, and complication rate.
CONCLUSIONS
Celecoxib is superior to diclofenac sodium in the treatment of KOA. However, well-designed and high-quality RCTs are still needed.
© The Author(s) 2020. Published by Oxford University Press on behalf of the American Academy of Pain Medicine.
Full Text Sources:
Miscellaneous:
Research Materials:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.